CN115444922B - Anti-fatigue medicinal and edible composition and application thereof - Google Patents
Anti-fatigue medicinal and edible composition and application thereof Download PDFInfo
- Publication number
- CN115444922B CN115444922B CN202211409447.5A CN202211409447A CN115444922B CN 115444922 B CN115444922 B CN 115444922B CN 202211409447 A CN202211409447 A CN 202211409447A CN 115444922 B CN115444922 B CN 115444922B
- Authority
- CN
- China
- Prior art keywords
- fatigue
- parts
- medicinal
- portions
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 240000000249 Morus alba Species 0.000 claims abstract description 10
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 10
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 10
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 10
- 235000008397 ginger Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 240000004510 Agastache rugosa Species 0.000 claims abstract description 9
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 9
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 5
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 244000273928 Zingiber officinale Species 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 235000007882 dietary composition Nutrition 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 42
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 206010016256 fatigue Diseases 0.000 description 16
- 230000009182 swimming Effects 0.000 description 12
- 238000001647 drug administration Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 241000234314 Zingiber Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920002527 Glycogen Polymers 0.000 description 5
- 230000037149 energy metabolism Effects 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 241001529821 Agastache Species 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to the technical field of traditional Chinese medicines, in particular to an anti-fatigue medicinal and edible homologous composition and application thereof, and specifically, the anti-fatigue medicinal and edible homologous composition provided by the invention comprises the following medicinal raw materials in parts by weight: 6 to 9 portions of cooked Pu' er tea, 3 to 6 portions of ginseng, 12 to 15 portions of coix seed, 3 to 6 portions of mulberry leaf, 3 to 6 portions of honeysuckle, 3 to 6 portions of kudzu root, 1 to 9 portions of wrinkled gianthyssop herb, 2 to 4 portions of raw liquorice, 2 to 4 portions of ginger and 2 to 4 portions of Chinese date. The anti-fatigue medicinal and edible composition can effectively relieve fatigue, and can provide a medicinal and edible combined product with good safety and good anti-fatigue effect for clinic. The traditional Chinese medicines in the whole formula of the anti-fatigue medicine-food homologous composition are both medicine-food homologous traditional Chinese medicines, and the preparation method is simple and convenient, safe and effective to eat, extremely easy to popularize and carry, and wide in market prospect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to an anti-fatigue medicinal and edible homologous composition and application thereof.
Background
Fatigue is one of the most common manifestations of sub-health and is a potential cause of the development of numerous diseases. Fatigue refers to a phenomenon that causes the physiological processes of the body to fail to continue their functions at a certain level and/or the organs to fail to maintain a predetermined exercise intensity, and if the body is over-fatigued for too long a duration to be relieved, organic diseases are caused. Therefore, the search for a medicine-food homologous combination with the anti-fatigue effect is one of the effective methods for regulating energy metabolism, regulating immunity, relieving fatigue and regulating sub-health state at the present time.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide an anti-fatigue medicinal and edible homologous composition and an application thereof, wherein the anti-fatigue medicinal and edible homologous composition can effectively relieve fatigue and can provide a medicinal and edible homologous combined product with good safety and good anti-fatigue effect for clinic.
In order to achieve the technical effect, the invention adopts the following technical scheme:
in a first aspect, the invention provides an anti-fatigue medicinal and edible homologous composition, which comprises the following medicinal raw material components: cooked Pu' er tea, ginseng, coix seed, mulberry leaf, honeysuckle flower, kudzuvine root, wrinkled gianthyssop herb, raw liquorice, ginger and Chinese date.
Further, the anti-fatigue medicinal and edible homologous composition comprises the following medicinal raw materials in parts by mass: 6 to 9 parts of cooked Pu' er tea, 3 to 6 parts of ginseng, 12 to 15 parts of coix seed, 3 to 6 parts of mulberry leaf, 3 to 6 parts of honeysuckle, 3 to 6 parts of kudzu root, 1 to 9 parts of wrinkled gianthyssop herb, 2 to 4 parts of raw liquorice, 2 to 4 parts of ginger and 2 to 4 parts of Chinese date.
Further, the anti-fatigue medicinal and edible homologous composition comprises the following medicinal raw materials in parts by mass: 6 parts of cooked Pu' er tea, 3 parts of ginseng, 12 parts of coix seed, 3 parts of mulberry leaf, 3 parts of honeysuckle flower, 3 parts of kudzuvine root, 6 parts of wrinkled gianthyssop herb, 2 parts of raw liquorice, 2 parts of ginger and 2 parts of Chinese date.
Furthermore, the anti-fatigue medicinal and edible homologous composition also comprises pharmaceutically acceptable auxiliary materials.
Further, the anti-fatigue medicinal and edible composition is prepared into any one of tablets, paste, powder, decoction, granules, capsules or dripping pills.
In a second aspect, the invention also provides application of the anti-fatigue medicinal and edible homologous composition in preparing anti-fatigue foods, health-care products or medicines.
Furthermore, the invention also provides application of the anti-fatigue medicinal and edible homologous composition in preparation of foods, health-care products or medicines for preventing and treating chronic fatigue syndrome.
In a third aspect, the invention also provides a preparation method of the anti-fatigue medicinal and edible homologous composition, which comprises the following steps:
s1: weighing the medicinal raw materials according to the formula, crushing, decocting for 2-3 times, combining liquid medicines obtained by multiple times of decoction, and cooling;
s2: and (3) concentrating the liquid medicine obtained in the step (S1) until a viscous paste-like liquid is obtained, and then drying the liquid medicine.
In addition, the S2 adopts a reduced pressure concentration method to concentrate the liquid medicine, and the evaporation temperature is 40-42 ℃, preferably 42 ℃.
Further, the reduced pressure concentration is carried out by reduced pressure rotary evaporation using a rotary evaporator.
Compared with the prior art, the invention has the beneficial effects that:
on the first hand, the anti-fatigue medicinal and edible homologous composition is prepared from natural medicinal and edible homologous Chinese herbal medicines, has a mild and continuous effect, does not cause severe stimulation and damage to organisms, has mild effect and good safety, has a good anti-fatigue effect, and is suitable for people of all ages to take. Meanwhile, animal experiments and clinical verification prove that the anti-fatigue medicinal and edible homologous composition can effectively relieve fatigue, is one of effective methods for adjusting energy metabolism, solving fatigue and adjusting sub-health states, and can provide a medicinal and edible homologous combined product with good safety and good anti-fatigue effect for clinical use.
In the second aspect, the invention is based on the basic theory of traditional Chinese medicine that the spleen governs the muscles of four limbs, and when the formula is used, the spleen is used as a starting point, and various medicines in the formula are reasonably and effectively used by taking the characteristics of strengthening the spleen, activating the spleen and activating the spleen, so that the effects of regulating energy metabolism, regulating immunity and resisting fatigue are achieved. In the formula, ginseng, ginger, liquorice, chinese date and cooked Pu' er are used for tonifying qi and strengthening spleen; honeysuckle, kudzu vine root and mulberry leaf for promoting the production of body fluid and strengthening the spleen; coix seed, semen Coicis and Agastaches herba, all of which resolve dampness and enliven the spleen. Although a plurality of medicines in the composition have certain anti-fatigue effect when used singly, the effect is not obvious when in use, and in the formula, the medicines are reasonably combined to ensure that the anti-fatigue effect is obvious, the composition plays a good anti-fatigue effect in animal experiments and clinical application, greatly plays a synergistic effect among the medicines, fully invigorates qi, invigorates spleen and engenders body fluid, and plays a role in resisting fatigue together.
Drawings
FIG. 1 is a statistical test result of swimming duration for each group of mice provided in example 5 of the present invention;
FIG. 2 is the statistics of the serum lactic acid (LD) content of each group of mice provided in example 5 of the present invention;
FIG. 3 is the statistical results of the serum urea nitrogen content of each group of mice provided in example 5 of the present invention;
FIG. 4 is a statistical result of serum liver glycogen content of each group of mice provided in example 5 of the present invention;
FIG. 5 shows the results of the HE staining of skeletal muscle of mice in each group, as provided in example 5 of the present invention;
FIG. 6 shows the experimental results of the skeletal muscles of the mice under electron microscope according to example 5 of the present invention;
FIG. 7 shows the results of the measurement of m-TORmRNA expression levels in each group of mice according to example 5 of the present invention;
FIG. 8 shows the results of the BeclinmRNA expression level assay in each group of mice provided in example 5 of the present invention;
FIG. 9 shows the results of the detection of the expression level of LC3mRNA from each group of mice provided in example 5 of the present invention;
FIG. 10 shows the results of measurement of the expression level of ULKmRNA in each group of mice provided in example 5 of the present invention.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to the accompanying drawings. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
Unless otherwise specified, the test methods used in the following examples are all conventional methods; the materials, reagents or instruments used are not indicated by manufacturers, and are all reagents and materials which are commercially available; the examples, which do not show the specific conditions, were conducted according to the conventional conditions or the conditions recommended by the manufacturer, and the sources of the raw materials used in the present invention are not limited, and the raw materials used in the present invention are all those commonly available in the art unless otherwise specified.
Example 1
This example is a first preparation example of the present invention, and provides an anti-fatigue pharmaceutical and edible composition and a preparation method thereof, specifically including:
in a first aspect, the present embodiment provides an anti-fatigue pharmaceutical and edible homologous composition, which includes the following pharmaceutical raw materials in parts by mass: 6 parts of cooked puerh, 3 parts of ginseng, 12 parts of coix seed, 3 parts of mulberry leaf, 3 parts of honeysuckle, 3 parts of kudzuvine root, 6 parts of wrinkled gianthyssop herb, 2 parts of raw liquorice, 2 parts of ginger and 2 parts of Chinese date.
In a second aspect, the present invention provides an anti-fatigue pharmaceutical-edible composition, which is prepared into a decoction, and the preparation method specifically comprises:
s1: weighing the medicinal raw materials according to the mass parts, crushing the medicinal raw materials, soaking the medicinal raw materials in deionized water with the volume of 10-15 times of that of the medicinal raw materials for half an hour, boiling the medicinal raw materials with strong fire, decocting the medicinal raw materials for 30 minutes with slow fire, filtering decoction dregs with gauze after the decoction, pouring the decoction dregs into a pot, decocting the decoction dregs for 2 times again, adding deionized water with the volume of 10 times of the decoction dregs during the second decoction, boiling the medicinal raw materials with strong fire, decocting the medicinal raw materials with slow fire for 30 minutes, and taking filtrate; adding deionized water 8 times the volume of the residue in the third decoction, boiling with strong fire, decocting with slow fire for 30 min, filtering to obtain filtrate, mixing the filtrates obtained after the three times of decoction to obtain medicinal liquid, and cooling to obtain decoction.
Example 2
This example is a second preparation example of the present invention, and provides an anti-fatigue dietetic and pharmaceutical composition and a preparation method thereof, specifically including:
in a first aspect, the present embodiment provides an anti-fatigue pharmaceutical and edible homologous composition, which includes the following pharmaceutical raw materials in parts by mass: 9 parts of cooked puerh, 6 parts of ginseng, 15 parts of coix seed, 6 parts of mulberry leaf, 6 parts of honeysuckle, 6 parts of kudzuvine root, 9 parts of wrinkled gianthyssop herb, 4 parts of raw liquorice, 4 parts of ginger and 4 parts of Chinese date.
In a second aspect, the anti-fatigue pharmaceutical and edible composition provided in this embodiment is prepared as an ointment, and the preparation method specifically includes:
s1: weighing the medicinal raw materials according to the parts by mass, and preparing the medicinal raw materials into decoction by referring to the method in example 1;
s2: and (3) further concentrating the decoction obtained in the step (S1), and performing reduced pressure rotary evaporation on the concentration by using a rotary evaporator, wherein the specific operation is as follows: pouring the cooled liquid into a rotary steaming bottle for multiple times, wherein the liquid poured each time cannot exceed one third of the total volume of the rotary steaming bottle, controlling the rotary steaming temperature to be 42 ℃, adjusting the rotary speed to 4 grades, adjusting the atmospheric pressure to 80 atmospheric pressures, reducing the atmospheric pressure according to the situation after the rotary steaming is started until the rotary steaming starts to be concentrated into viscous near-pasty liquid, pouring the viscous near-pasty liquid into a glass vessel, and drying the viscous near-pasty liquid in a drying box to be pasty to obtain the paste.
Example 3
This example is a third preparation example of the present invention, and provides an anti-fatigue pharmaceutical and edible composition and a preparation method thereof, specifically including:
in a first aspect, the present embodiment provides an anti-fatigue pharmaceutical and edible composition, which includes the following pharmaceutical raw materials in parts by mass: 8 parts of cooked puerh, 5 parts of ginseng, 13 parts of coix seed, 4 parts of mulberry leaf, 4 parts of honeysuckle, 5 parts of kudzuvine root, 7 parts of wrinkled gianthyssop herb, 3 parts of raw liquorice, 3 parts of ginger and 3 parts of Chinese date.
In a second aspect, the present embodiment provides an anti-fatigue pharmaceutical-edible composition, which is prepared into a tablet, and the preparation method specifically comprises the following steps:
s1: weighing the medicinal raw materials according to the mass parts, performing percolation extraction by using 50% ethanol as an extraction solvent, soaking the medicinal raw materials by using 1-3 times of the volume of the solvent before extraction, then extracting by using 8-9 times of the volume of the solvent, controlling the flow rate of percolation extraction at 4-5 ml/min, and obtaining an extracting solution after extraction;
s2: and (2) further carrying out reduced pressure rotary evaporation on the extracting solution obtained in the step (S1) by using a rotary evaporator to obtain viscous near-pasty liquid, adding auxiliary materials including a filling agent and a lubricating agent into the viscous near-pasty liquid, and carrying out wet granulation to prepare tablets, wherein the filling agent and the lubricating agent can be selected from the prior art.
Example 4
This example is a fourth preparation example of the present invention, and provides an anti-fatigue dietetic composition and a preparation method thereof, specifically including:
in a first aspect, the present embodiment provides an anti-fatigue pharmaceutical and edible homologous composition, which includes the following pharmaceutical raw materials in parts by mass: 8 parts of cooked puerh, 5 parts of ginseng, 13 parts of coix seed, 4 parts of mulberry leaf, 4 parts of honeysuckle, 5 parts of kudzuvine root, 1 part of wrinkled gianthyssop herb, 3 parts of raw liquorice, 3 parts of ginger and 3 parts of Chinese date.
In a second aspect, the present embodiment provides an anti-fatigue pharmaceutical and edible composition, which is prepared into a chewing gum with health care function, so that the composition can be taken by patients at any time, and is more acceptable to patients in terms of dosage form, and the preparation method specifically comprises the following steps:
s1: weighing the medicinal raw materials according to the mass parts, performing percolation extraction by using 50% ethanol as an extraction solvent, soaking the medicinal raw materials by using 1-3 times of volume of the solvent before extraction, then extracting by using 8-9 times of volume of the solvent, controlling the flow rate of percolation extraction at 4-5 ml/min, and obtaining an extracting solution after extraction is completed;
s2: and (2) further carrying out reduced pressure rotary evaporation on the extracting solution obtained in the step (S1) by using a rotary evaporator to obtain viscous near-paste liquid, taking the viscous near-paste liquid as a raw material, and adding a gum base, a flavoring agent, an antioxidant, a filler and the like in the preparation process to prepare the chewing gum. Wherein, the gum base, the flavoring agent, the antioxidant, the filling agent and the like can be selected from the prior art.
Example 5
The embodiment is an embodiment for verifying the efficacy and safety of the invention, and specifically comprises the following steps:
70 SPF male Kunming mice of 4 weeks are selected, after the mice are fed adaptively for one week in an animal room with the temperature of about 25 ℃ and the humidity of 50-60%, 50 mice which can swim are selected in a swimming experiment and randomly divided into 5 groups, 10 mice in each group are respectively marked as a blank group, a model group, a low-dose group, a medium-dose group and a high-dose group, wherein the blank group and the model group are dosed by pure water, the low-dose group, the medium-dose group and the high-dose group are dosed for four weeks as dosing groups, the three dosing groups use the decoction prepared in example 1 as dosing medicines, the dosing medicines are respectively prepared into three dosing doses of low, medium and high, and the dosing doses of the low-dose group, the medium-dose group and the high-dose group are respectively 2.73g/kg, 5.46/kg and 10.92g/kg.
5.1 Observe the effect of drug administration on the swimming duration of mice
The three administration groups are respectively administered with three administration dosages of low, medium and high drugs for four weeks continuously, one hour after the last administration, the mice of the model group, the low dose group, the medium dose group and the high dose group are subjected to exhaustive swimming experiments, a lead wire with the weight of 5 percent of the weight of the mice is bound on the tail root of the mice, the mice are subjected to weight-bearing swimming in a water tank with the water depth of 40cm at the temperature of 30 ℃, the time that the mice of each group can not float out of the water surface after sinking into the water surface for 8 seconds is recorded as the swimming time of the mice, and the experimental result is shown in figure 1.
The experimental results show that the swimming time of the mice in the administration group (low dose group, medium dose group, and high dose group) is significantly prolonged (P < 0.01) compared to the model group (no administration).
5.2 Observe the influence of the drug administration on the serum lactic acid, urea nitrogen and liver glycogen content of the mice
After the mice in each group were subjected to the weight swimming experiment, blood and liver were collected after the mice had a rest for 60 minutes, the weight and body mass of the liver of the mice were recorded and left on ice for one hour, then the serum was separated at 2500 rpm for 10 minutes, and the contents of lactic acid (LD), urea nitrogen (BUN) and hepatic glycogen (LG) in the serum of the mice were measured according to the instructions of the kit, and the experimental results are shown in fig. 2, fig. 3 and fig. 4, respectively.
The experimental results in fig. 2 show that the content of lactic acid (LD) in the fatigue model mice can be significantly reduced after administration, and the LD content in the model group is significantly increased (P < 0.01) compared with the blank group. The LD content of the mice in the administration group was significantly reduced (P < 0.01) compared with that in the model group.
The experimental results in fig. 3 show that the urea nitrogen (BUN) content of the fatigue model mice can be reduced after administration, and the urea nitrogen (BUN) content of the model group is significantly increased (P < 0.01) compared with that of the blank group. The urea nitrogen (BUN) content of the administered group was significantly reduced (P < 0.01) compared to the model group.
The experimental results in FIG. 4 show that the content of hepatic glycogen (LG) of the fatigue model mouse can be increased after administration, and the LG content of the model group is obviously reduced compared with that of the blank group (P < 0.01). The LG content of the administered group was significantly increased (P < 0.01) compared to the model group.
5.3 The effect of drug administration on mouse liver index was observed to verify drug safety
In this example, liver indexes of five groups of mice were measured, and the results are shown in table 1:
TABLE 1 Observation of the Effect of drug administration on the liver index of mice
| Group of | Liver Organ Index |
| Blank space | 0.0456±0.0023 |
| Model (model) | 0.0463±0.0054 |
| Low dose group | 0.0464±0.0030 |
| Middle dose group | 0.0449±0.0037 |
| High dose group | 0.0475±0.0057 |
The experimental results show that the continuous administration for four weeks has no obvious influence on the liver index of the mice, and the anti-fatigue medicine and food homologous composition is proved to have no damage to the mice and is a safe, reliable and effective medicine and food homologous combination.
5.4 Observation of the Effect of the drug administration (Medium dose) on the skeletal muscle of mice
5.4.1 HE staining experiment
Five groups of mice were dissected and HE-stained for skeletal muscle of the mice, and the results are shown in fig. 5.
The experimental results show that HE staining observed the blank group of skeletal muscle fibers with regular and clear transverse striations and complete muscle cell nucleus. The skeletal muscle cells of the model group are damaged and fused, muscle fibers are damaged in different degrees and are arranged irregularly, inflammatory cell infiltration is caused, the gap between the muscle fibers is increased, the shape is irregular, and the phenomenon of nucleus centering is caused. The muscle fiber gaps of the administration groups (including the low-dose group, the medium-dose group and the high-dose group) become small, the arrangement is compact, the shapes of muscle cells are improved, and the distribution rule of cell nuclei is regular.
5.4.1 Electron microscope experiment
The five groups of mice are dissected, and the skeletal muscles of the mice are observed under an electron microscope, and the experimental results are shown in the attached figure 6.
The results of this experiment showed that the blank group was morphologically normal and formation of autophagosomes was observed. In the model group, the gastrocnemius fibers were disorganized, the mitochondria were swollen and vacuolated, the mitochondrial volume was abnormally increased with an increase in mitochondrial matrix, and the symptoms of the model were reduced after administration, compared to the blank group.
5.5 Observation of the effects of drug administration on the expression levels of m-TORmRNA, beclinmRNA, LC3mRNA and ULKmRNA in mice
5.5.1 Observation of the effects of drug administration on the expression level of m-TORmRNA in mice
After the swimming test, m-TORmRNA expression level of each group of mice was measured, and the test results are shown in FIG. 7.
The experimental results show that compared with the blank group, the mTORmRNA expression of the model group is obviously increased. The administration group showed a significant decrease in mtorr mrna expression compared to the model group (. P < 0.05).
5.5.2 Observation of the Effect of drug administration on the expression level of mouse BeclinmRNA
After the swimming test, the beclin mrna expression level of each group of mice was measured, and the test results are shown in fig. 8.
The experimental results show that the beclin mrna expression of the model group is significantly reduced compared with that of the blank group. The beclin mrna expression was significantly increased in the administered group compared to the model group (. P < 0.05).
5.5.3 Observation of the Effect of drug administration on mouse LC3mRNA expression levels
After the swimming test, the expression level of LC3mRNA was measured in each group of mice, and the test results are shown in fig. 9.
The experimental results show that the LC3mRNA expression of the model group was significantly reduced compared to the blank group. LC3mRNA expression was significantly increased in each group administered compared to the model group (. P < 0.05).
5.5.4 Observation of the Effect of drug administration on the expression levels of mouse ULKmRNA
After the weight swimming experiment, the expression level of ULKmRNA of each group of mice was measured, and the experimental results are shown in fig. 10.
The experimental results show that the ULKmRNA expression of the model group was significantly reduced compared to the blank group. ULKmRNA expression was significantly increased in each group administered compared to the model group (. P < 0.05).
The experimental results show that the anti-fatigue pharmaceutical and edible composition provided by the embodiment can activate an mTOR autophagy signal pathway by regulating autophagy-related factors (LC 3, beclin, ULK, and the like), enhance energy metabolism of skeletal muscle mitochondria of a fatigue mouse, improve fatigue index contents of lactic acid, urea nitrogen, glycogen, and the like in the fatigue mouse, and have an anti-fatigue effect, and the effect is remarkable.
Based on the research, the anti-fatigue medicinal and edible composition can effectively relieve fatigue, is one of effective methods for adjusting energy metabolism, solving fatigue and adjusting sub-health state, and can provide a medicinal and edible combined product with good safety and good anti-fatigue effect for clinic.
Although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the spirit and scope of the invention as defined in the appended claims. The techniques, shapes, and configurations not described in detail in the present invention are all known techniques.
Claims (7)
1. The anti-fatigue medicinal and edible homologous composition is characterized by being prepared from the following medicinal raw materials in parts by mass: 6 parts of cooked Pu' er tea, 3 parts of ginseng, 12 parts of coix seed, 3 parts of mulberry leaf, 3 parts of honeysuckle flower, 3 parts of kudzuvine root, 6 parts of wrinkled gianthyssop herb, 2 parts of raw liquorice, 2 parts of ginger and 2 parts of Chinese date.
2. The anti-fatigue pharmaceutical-dietary homologous composition of claim 1, wherein said anti-fatigue pharmaceutical-dietary homologous composition further comprises a pharmaceutically acceptable adjuvant.
3. An anti-fatigue nutraceutical homologous composition as claimed in claim 1, wherein: the anti-fatigue medicinal and edible composition is prepared into any one of tablets, paste, powder, decoction, granules, capsules or dripping pills.
4. The use of the anti-fatigue pharmaceutical-edible homologous composition as claimed in claim 1 in the preparation of anti-fatigue health care products or medicines.
5. Use of the anti-fatigue pharmaceutical-edible homologous composition as claimed in claim 1 for preparing a medicament for preventing and treating chronic fatigue syndrome.
6. The process for preparing an antifatigue dietary composition according to claim 1 comprising the steps of:
s1: weighing the medicinal raw materials according to the formula, crushing, decocting for 2-3 times, combining liquid medicines obtained by multiple times of decoction, and cooling;
s2: and (3) concentrating the liquid medicine obtained in the step (S1) until viscous paste-like liquid is obtained, and then drying the liquid medicine.
7. The process for preparing an antifatigue medicinal composition according to claim 6 wherein said step S2 is carried out by concentrating under reduced pressure and evaporating at 40-42 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211409447.5A CN115444922B (en) | 2022-11-11 | 2022-11-11 | Anti-fatigue medicinal and edible composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211409447.5A CN115444922B (en) | 2022-11-11 | 2022-11-11 | Anti-fatigue medicinal and edible composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115444922A CN115444922A (en) | 2022-12-09 |
| CN115444922B true CN115444922B (en) | 2023-02-03 |
Family
ID=84295687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211409447.5A Active CN115444922B (en) | 2022-11-11 | 2022-11-11 | Anti-fatigue medicinal and edible composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115444922B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115779039B (en) * | 2023-01-30 | 2023-05-16 | 云南中医药大学 | Pharmaceutical composition for treating postmenopausal osteoporosis |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1104060A (en) * | 1994-08-20 | 1995-06-28 | 大连医科大学附属第一医院绿洲营养保健研究所 | Plant-type chinese traditional medicinal meal |
| CN101347252A (en) * | 2007-07-16 | 2009-01-21 | 康钢山 | Rainbow health care drink |
| CN104258327A (en) * | 2014-09-19 | 2015-01-07 | 河南福森药业有限公司 | Health granules for boosting immunity and preparation method of health granules |
| CN106474341A (en) * | 2016-11-09 | 2017-03-08 | 重庆壹通堂健康管理咨询有限公司 | A kind of Chinese medicine formula filling blood |
| CN106473099A (en) * | 2016-10-12 | 2017-03-08 | 钟术光 | Functional food or alternative tea that effect improves |
| CN110477177A (en) * | 2019-08-15 | 2019-11-22 | 朱保全 | A kind of ginseng pueraria lobata pressed candy and preparation method thereof |
| CN111616246A (en) * | 2020-05-27 | 2020-09-04 | 包头金氏中医肾病医院有限责任公司 | Health tea and its prepn |
| CN111905084A (en) * | 2020-08-07 | 2020-11-10 | 浙江金城阜通制药有限公司 | Traditional Chinese medicine extract and preparation process and application thereof |
| CN114052109A (en) * | 2021-12-22 | 2022-02-18 | 天津市元生泰科技有限公司 | Medicinal and edible health tea and preparation method thereof |
| CN114600989A (en) * | 2022-03-29 | 2022-06-10 | 广东红珊瑚药业有限公司 | Instant tea composition and preparation method thereof |
-
2022
- 2022-11-11 CN CN202211409447.5A patent/CN115444922B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1104060A (en) * | 1994-08-20 | 1995-06-28 | 大连医科大学附属第一医院绿洲营养保健研究所 | Plant-type chinese traditional medicinal meal |
| CN101347252A (en) * | 2007-07-16 | 2009-01-21 | 康钢山 | Rainbow health care drink |
| CN104258327A (en) * | 2014-09-19 | 2015-01-07 | 河南福森药业有限公司 | Health granules for boosting immunity and preparation method of health granules |
| CN106473099A (en) * | 2016-10-12 | 2017-03-08 | 钟术光 | Functional food or alternative tea that effect improves |
| CN106474341A (en) * | 2016-11-09 | 2017-03-08 | 重庆壹通堂健康管理咨询有限公司 | A kind of Chinese medicine formula filling blood |
| CN110477177A (en) * | 2019-08-15 | 2019-11-22 | 朱保全 | A kind of ginseng pueraria lobata pressed candy and preparation method thereof |
| CN111616246A (en) * | 2020-05-27 | 2020-09-04 | 包头金氏中医肾病医院有限责任公司 | Health tea and its prepn |
| CN111905084A (en) * | 2020-08-07 | 2020-11-10 | 浙江金城阜通制药有限公司 | Traditional Chinese medicine extract and preparation process and application thereof |
| CN114052109A (en) * | 2021-12-22 | 2022-02-18 | 天津市元生泰科技有限公司 | Medicinal and edible health tea and preparation method thereof |
| CN114600989A (en) * | 2022-03-29 | 2022-06-10 | 广东红珊瑚药业有限公司 | Instant tea composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 八珍汤加减治疗慢性疲劳综合征;耿以安;《吉林中医药》;20051220;第25卷(第12期);第22页 * |
| 臭参的降血脂抗疲劳及抗缺氧作用研究;董丽丹，等;《云南中医中药杂志》;20150320;第36卷(第03期);第66-68页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115444922A (en) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106492110B (en) | Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation | |
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| CN115444922B (en) | Anti-fatigue medicinal and edible composition and application thereof | |
| KR20110042772A (en) | The health foods for antithrombotic effectiveness containing extracts of crude drug | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| KR20200136207A (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| EP3881685A1 (en) | Ceratonia siliqua fruit composition and preparation method therefor and use thereof | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN102688471A (en) | Compound preparation for preventing fatigue | |
| CN108143974A (en) | Relieving alcoholism and protecting liver ball | |
| WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
| CN108576346A (en) | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid | |
| CN101085076A (en) | Chinese and Western medicine united sustained-release injection for preventing and controlling coccidiosis of rabbit and its preparation method | |
| CN104622993B (en) | Chewable tablet with protective effect on alcoholic liver injuries and preparation method of chewable tablet | |
| CN104474337B (en) | A kind of preparation method containing in green-tea extract into health instant powder | |
| WO2014098295A1 (en) | Composition for preventing or treating oxidative brain damage and brain dysfunction, and production method for same | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN110420320A (en) | A kind of Chinese medicine composition for removing gout pathogenesis basis | |
| CN104474406A (en) | Health traditional Chinese medicine wine for nourishing yin and moistening lung and preparation method of health traditional Chinese medicine wine | |
| US20190365841A1 (en) | Composition having functions of improving kidney yang, enhancing immunity and relieving fatigue, method for producing the same and use thereof | |
| CN108477372A (en) | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar anti-aging tranquilizing effect | |
| CN103877513A (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |